Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

NCT00146601 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
35
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Dana-Farber Cancer Institute

Collaborators